|
Malignant neoplasm of breast
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
The expression of FHL2 is found in different tissues and organs and has been reported as a critical participant influencing the wide types of cancer such as breast cancer, gastrointestinal (GI) cancers, liver cancer and prostate cancer.
|
26211626 |
2015 |
|
Breast Carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
The expression of FHL2 is found in different tissues and organs and has been reported as a critical participant influencing the wide types of cancer such as breast cancer, gastrointestinal (GI) cancers, liver cancer and prostate cancer.
|
26211626 |
2015 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
The functional roles of FHL2-Id3 signaling in the development of human breast cancer need further research.
|
22882857 |
2012 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
The functional roles of FHL2-Id3 signaling in the development of human breast cancer need further research.
|
22882857 |
2012 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
CTD_human |
Finally, downregulation of FHL2 reduces the ability of MDA-MB 231 cells to form colonies in soft agar, while FHL2 overexpression enhances colony formation of breast cancer cells.
|
17682292 |
2007 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
Here we analyzed for the first time the molecular function of FHL2 in breast cancer.
|
17682292 |
2007 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Here we analyzed for the first time the molecular function of FHL2 in breast cancer.
|
17682292 |
2007 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
CTD_human |
Finally, downregulation of FHL2 reduces the ability of MDA-MB 231 cells to form colonies in soft agar, while FHL2 overexpression enhances colony formation of breast cancer cells.
|
17682292 |
2007 |
|
Malignant neoplasm of breast
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Reverse transcription polymerase chain reaction analysis showed that FHL2 mRNA levels may be downregulated in many breast cancer cell lines.
|
14550570 |
2003 |
|
Breast Carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Reverse transcription polymerase chain reaction analysis showed that FHL2 mRNA levels may be downregulated in many breast cancer cell lines.
|
14550570 |
2003 |
|
Malignant neoplasm of breast
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, down-regulation of DRAL was not confined to the RD RMS cells, but was a phenomenon extended to other RMS cell lines of both embryonal and alveolar subtype, and to some breast cancer cell lines.
|
9150430 |
1997 |
|
Breast Carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, down-regulation of DRAL was not confined to the RD RMS cells, but was a phenomenon extended to other RMS cell lines of both embryonal and alveolar subtype, and to some breast cancer cell lines.
|
9150430 |
1997 |
|
Mammary Neoplasms
|
0.320 |
AlteredExpression
|
group |
LHGDN |
FHL2 regulates cell cycle-dependent and doxorubicin-induced p21Cip1/Waf1 expression in breast cancer cells.
|
17682292 |
2007 |
|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
CTD_human |
FHL2 regulates cell cycle-dependent and doxorubicin-induced p21Cip1/Waf1 expression in breast cancer cells.
|
17682292 |
2007 |
|
Mammary Neoplasms
|
0.320 |
AlteredExpression
|
group |
LHGDN |
Expression of the transcriptional coregulator FHL2 in human breast cancer: a clinicopathologic study.
|
16378916 |
2006 |
|
Leukemia, Myelocytic, Acute
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Our results suggested that high expressions of FHL2 and iASPP were poor prognostic factors for AML, but the prognostic effect might be overcome by allo-HSCT.
|
29910468 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.310 |
Biomarker
|
disease |
CTD_human |
Discovery of epigenetically silenced genes in acute myeloid leukemias.
|
17330099 |
2007 |
|
Cardiomegaly
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
FHL2 expression and variants in hypertrophic cardiomyopathy.
|
25358972 |
2014 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Cardiac Hypertrophy
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Based on evidence that FHL2 (four and a half LIM domains protein 2) negatively regulates cardiac hypertrophy we tested whether FHL2 altered expression or variants could be associated with hypertrophic cardiomyopathy (HCM).
|
25358972 |
2014 |
|
Acute Myeloid Leukemia, M1
|
0.300 |
Biomarker
|
disease |
CTD_human |
Discovery of epigenetically silenced genes in acute myeloid leukemias.
|
17330099 |
2007 |
|
Familial dilated cardiomyopathy
|
0.300 |
GermlineCausalMutation
|
disease |
ORPHANET |
Structural analysis of four and half LIM protein-2 in dilated cardiomyopathy.
|
17416352 |
2007 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
FHL2 regulates cell cycle-dependent and doxorubicin-induced p21Cip1/Waf1 expression in breast cancer cells.
|
17682292 |
2007 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.300 |
Biomarker
|
disease |
CTD_human |
Discovery of epigenetically silenced genes in acute myeloid leukemias.
|
17330099 |
2007 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
FHL2 is overexpressed in almost all human mammary carcinoma samples tested but not in normal breast tissues and only low levels of FHL2 expression were present in four premalignant ductal carcinoma in situ (DCIS).
|
17682292 |
2007 |